2023年2月，中概股赴美上市继续回暖，收获了多个“第一”项目。中伦律师事务所合伙人贾海波在接受《证券时报》采访中指出，目前可以说赴美上市窗口期已来，但全面回暖尚需时日。
- 硕迪生物登陆纳斯达克
2月3日，生物制药公司硕迪生物在纳斯达克成功上市，募资额约为1.61亿美元。硕迪生物是经历中概股审计风波等后首家破冰美股的中美合作生物医疗企业，成为了数月以来规模最大的生物科技领域美国上市项目。
中伦律师事务所、美国科律律师事务所为发行人提供法律服务；君合律师事务所、瑞生国际律师事务所则为承销商提供法律服务。
硕迪生物是一家处于临床阶段的全球生物医药企业，致力于开发应用新型口服疗法，以治疗各类尚无对症的慢性疾病，例如2型糖尿病、肥胖症、肺部疾病等。
科律团队由全球资本市场业务联席负责人Charlie Kim、合伙人陆培祥(Patrick Loofbourrow)、Andrew Harline领衔；中伦团队由合伙人赵靖、贾海波牵头；君合团队由合伙人叶宇嵘、陈燕领衔；瑞生团队由合伙人Matt Bush、Cheston Larson领导。
- 禾赛科技登陆纳斯达克
2月9日，“中国激光雷达第一股”禾赛科技登陆纳斯达克，募集资金1.9亿美元，成为2021年中期以来融资规模最大的中概股IPO。
通商律师事务所、世达国际律师事务所为发行人律师；方达律师事务所、瑞生国际律师事务所则为承销商提供法律服务。
禾赛科技创立于2014年，是全球激光雷达技术行业的领军企业，产品广泛应用于支持高级辅助驾驶系统的乘用车和商用车，以及自动驾驶汽车，其激光雷达技术也致力赋能各类机器人应用。
方达团队由合伙人丁继栋、王梦婕、刘刚牵头；瑞生团队由香港办事处合伙人王嘉忻、施道明领导。
- 亚创集团通过De-SPAC登陆纽交所
总部位于新加坡的亚洲创新集团（亚创集团）宣布其与特殊目的收购公司Magnum Opus Acquisition Limited （OPA）达成并购协议，交易完成后，亚创集团将于纽约证券交易所上市。此次SPAC合并将为亚创集团带来约2亿美元的收益，这合并完成后可能再筹集1.5亿美元。
凯易国际律师事务所为亚创集团提供法律服务；君合律师事务所、伟凯律师事务所则担任OPA的法律顾问。
亚创集团成立于2013年，是一家涵盖社交、手机游戏、电子商务和支付业务的综合移动互联网生态平台。根据咏竹坊信息，该公司背景十分中国化，其高管几乎都是中国高科技领域的第二代创业者。
OPA则是第一批创立于中国的SPAC公司，总部位于香港。其曾寻求与福布斯达成合并而未果。
君合团队由合伙人桑滨学、李新杰领导；凯易国际团队由合伙人Jesse Sheley、张彤、林邦、Joseph Raymond Casey、周游牵头；伟凯团队由合伙人谢智海、周叶萍、Joel Rubinstein领衔。
Deal Digest: Chinese companies show increased appetite on U.S. capital markets
This February, the listing of Chinese concept stocks in the U.S. continued to pick up, harvesting a number of first-of-its-kind projects.
NASDAQ – STRUCTURE THERAPEUTICS
Cooley and Zhong Lun Law Firm have advised biotech company Structure Therapeutics on its $161 million IPO on Nasdaq, with JunHe and Latham & Watkins advising the joint sponsors. This transaction is the largest biotech U.S. IPO in recent months.
Structure Therapeutics is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs.
The Cooley team was led by partners Charlie Kim, Patrick Loofbourrow and Andrew Harline; the Zhong Lun team was led by partners Anthony Zhao and William Jia; The JunHe team was led by partners Ye Yurong and Chen Yan; and the Latham team was led by partners Matt Bush and Cheston Larson.
NASDAQ – HESAI GROUP
Skadden, Arps, Slate, Meagher & Flom, Commerce & Finance Law Offices have advised Hesai Group on its $190 million IPO on Nasdaq, with Latham & Watkins and Fangda Partners advising the joint sponsors.
This transaction is the largest U.S. IPO by a mainland Chinese company since the mid of 2021. According to Fangda, Hesai became “China’s first LiDAR stock” through this successful listing.
Founded in 2014, Hesai is the global leader in three-dimensional light detection and ranging (LiDAR) solutions. The Company’s LiDAR products enable a broad spectrum of applications across passenger and commercial vehicles with advanced driver assistance systems and autonomous vehicle fleets.
The Fangda team was led by partners Jeffrey Ding, Mengjie Wang and Brian Liu; The Latham team was led by partners Allen Wang and Dominik Sklenar.
NYSE – ASIA INNOVATION GROUP
Singapore-based mobile app developer Asia Innovations Group Limited (ASIG) will go public on the New York Stock Exchange through a merger with SPAC vehicle Magnum Opus Acquisition Limited (OPA). This merger will bring in nearly $200 million for ASIG, and the company plans to raise another $150 million when the deal is completed.
Kirkland & Ellis advised ASIG in the deal, with JunHe and White & Case advising OPA.
Established in 2013, ASIG develops internet products and services, and its product portfolio spans video, social dating, games, e-commerce and payment platforms.
The JunHe team was led by partners Sang Binxue and Li Xinjie; the Kirkland team was led by partners Jesse Sheley, David Zhang, Steve Lin, Joseph Raymond Casey, and Justin Zhou; and the White & Case team was led by partners Steve Sha, Jessica Zhou and Joel Rubinstein.
